WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 200185
CAS#: 1002304-34-8
Description: AMG 208 is a selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 208 inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity, which may result in cell growth inhibition in tumors that overexpress c-Met. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase, plays an important role in epithelial cell proliferation and has been shown to be overexpressed in a variety of cancers.
MedKoo Cat#: 200185
Name: AMG208
CAS#: 1002304-34-8
Chemical Formula: C22H17N5O2
Exact Mass: 383.13822
Molecular Weight: 383.4
Elemental Analysis: C, 68.92; H, 4.47; N, 18.27; O, 8.35
AMG-208, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: AMG208; AMG 208; AMG-208.
IUPAC/Chemical Name: 4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]-7-methoxyquinoline
InChi Key: HEAIZQNMNCHNFD-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H17N5O2/c1-28-16-7-8-17-19(13-16)23-12-11-20(17)29-14-22-25-24-21-10-9-18(26-27(21)22)15-5-3-2-4-6-15/h2-13H,14H2,1H3
SMILES Code: COC1=CC=C2C(OCC3=NN=C4C=CC(C5=CC=CC=C5)=NN43)=CC=NC2=C1
The following data is based on the product molecular weight 383.4 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
AMG-208 is currently developed and investigated by Amgen as an anticancer drug candidate. Amgen-208 inhibits both ligand-dependent and ligand-independent c-Met activation. As of 2010, Amgen is in phase 1 clinical trials. (source: http://clinicaltrials.gov/ct2/show/NCT00813384).